Arild Hetland1,2, Maria Vistnes3, Kristina H Haugaa2,4, Kristian Hovde Liland5, Margareth Olseng1, Thor Edvardsen2,4. 1. Department of Cardiology, The Hospital of Oestfold, Oestfold, Norway. 2. Faculty of Medicine, University of Oslo, Oslo, Norway. 3. Department of Internal Medicine, Diakonhjemmet Hospital, Oslo, Norway. 4. Department of Cardiology and Center for Cardiological Innovation, Oslo University Hospital, Rikshospitalet Oslo, Oslo, Norway. 5. Faculty of Science and Technology, Norwegian University of Life Sciences, Ås, Norway.
Abstract
BACKGROUND: In chronic heart failure (CHF), obstructive sleep apnea (OSA) and Cheyne-Stokes respiration (CSR) are associated with increased mortality. The present study aimed to evaluate the prognostic effect of CSR compared to OSA, in otherwise similar groups of CHF patients. METHODS: Screening for sleep-disordered breathing (SDB) was conducted among patients with CHF of New York Heart Association (NYHA) class II-IV, and left ventricular ejection fraction (LVEF) of ≤45%. The study included 43 patients (4 women) with >25% CSR during sleeping time, and 19 patients (2 women) with OSA and an apnea-hypopnea index (AHI) of ≥6. Patients were followed for a median of 1,371 days. The primary endpoint was mortality, and the secondary endpoint was combined mortality and hospital admissions. RESULTS: Baseline parameters did not significantly differ between groups, but CSR patients were older and had higher AHI values than OSA patients. Five OSA patients (26%) died, and 14 (74%) met the combined end-point of death or hospitalization. CSR patients had significantly higher risk for both end-points, with 23 (53%) deaths [log-rank P=0.040; HR, 2.70 (1.01-7.22); P=0.047] and 40 (93%) deaths or readmissions [log-rank P=0.029; HR, 1.96 (1.06-3.63); P=0.032]. After adjustment for confounding risk factors, the association between CSR and death remained significant [HR, 4.73 (1.10-20.28); P=0.037], hospital admission rates were not significantly different. CONCLUSIONS: Among patients with CHF, CSR was associated with higher mortality than OSA independently of age and cardiac systolic function. CSR was also an age-independent predictor of unfavorable outcome, but hospital admission rates were not significantly different between the two groups after adjustment. 2020 Cardiovascular Diagnosis and Therapy. All rights reserved.
BACKGROUND: In chronic heart failure (CHF), obstructive sleep apnea (OSA) and Cheyne-Stokes respiration (CSR) are associated with increased mortality. The present study aimed to evaluate the prognostic effect of CSR compared to OSA, in otherwise similar groups of CHF patients. METHODS: Screening for sleep-disordered breathing (SDB) was conducted among patients with CHF of New York Heart Association (NYHA) class II-IV, and left ventricular ejection fraction (LVEF) of ≤45%. The study included 43 patients (4 women) with >25% CSR during sleeping time, and 19 patients (2 women) with OSA and an apnea-hypopnea index (AHI) of ≥6. Patients were followed for a median of 1,371 days. The primary endpoint was mortality, and the secondary endpoint was combined mortality and hospital admissions. RESULTS: Baseline parameters did not significantly differ between groups, but CSR patients were older and had higher AHI values than OSA patients. Five OSA patients (26%) died, and 14 (74%) met the combined end-point of death or hospitalization. CSR patients had significantly higher risk for both end-points, with 23 (53%) deaths [log-rank P=0.040; HR, 2.70 (1.01-7.22); P=0.047] and 40 (93%) deaths or readmissions [log-rank P=0.029; HR, 1.96 (1.06-3.63); P=0.032]. After adjustment for confounding risk factors, the association between CSR and death remained significant [HR, 4.73 (1.10-20.28); P=0.037], hospital admission rates were not significantly different. CONCLUSIONS: Among patients with CHF, CSR was associated with higher mortality than OSA independently of age and cardiac systolic function. CSR was also an age-independent predictor of unfavorable outcome, but hospital admission rates were not significantly different between the two groups after adjustment. 2020 Cardiovascular Diagnosis and Therapy. All rights reserved.
Authors: Martin R Cowie; Holger Woehrle; Karl Wegscheider; Christiane Angermann; Marie-Pia d'Ortho; Erland Erdmann; Patrick Levy; Anita K Simonds; Virend K Somers; Faiez Zannad; Helmut Teschler Journal: N Engl J Med Date: 2015-09-01 Impact factor: 91.245
Authors: Jeptha P Curtis; Seth I Sokol; Yongfei Wang; Saif S Rathore; Dennis T Ko; Farid Jadbabaie; Edward L Portnay; Stephen J Marshalko; Martha J Radford; Harlan M Krumholz Journal: J Am Coll Cardiol Date: 2003-08-20 Impact factor: 24.094
Authors: D Yumino; H Wang; J S Floras; G E Newton; S Mak; P Ruttanaumpawan; J D Parker; T D Bradley Journal: Heart Date: 2009-01-08 Impact factor: 5.994
Authors: Andrew P Ambrosy; Gregg C Fonarow; Javed Butler; Ovidiu Chioncel; Stephen J Greene; Muthiah Vaduganathan; Savina Nodari; Carolyn S P Lam; Naoki Sato; Ami N Shah; Mihai Gheorghiade Journal: J Am Coll Cardiol Date: 2014-02-05 Impact factor: 24.094
Authors: Michael D Faulx; Reena Mehra; Glaucylara Reis Geovanini; Shin-Ichi Ando; Michael Arzt; Luciano Drager; Michael Fu; Camilla Hoyos; Jo Hai; Juey-Jen Hwang; Remzi Karaoguz; John Kimoff; Pei-Lin Lee; Olga Mediano; Sanjay R Patel; Yüksel Peker; Jean Louis Pepin; Manuel Sanchez-de-la-Torre; Frédéric Sériès; Stefan Stadler; Patrick Strollo; A A Tahrani; Erik Thunström; Motoo Yamauchi; Susan Redline; Craig L Phillips Journal: Int J Cardiol Heart Vasc Date: 2022-07-19